Slide 1: Activate Your Body to Deactivate Cancer
ACTIVATE YOUR BODY TO DEACTIVATE CANCER Faron’s Financial Statement Release 2024 1 27-FEB-2025 FINANCIAL STATEMENT RELEASE 2024
Slide 2: Corporate Disclaimer
Corporate Disclaimer The contents of this presentation have not been approved by an authorized person within the meaning of Section 21 of the Financial Services and Markets Act 2000 (as amended) ("FSMA"). Reliance on the contents of this presentation for the purpose of engaging in any investment act
Slide 3: Today's agenda and presenters
Today’s agenda and presenters Financial Results 2024 Yrjö Wichmann, CFO, Faron Faron’s transformative year 2024 Dr. Juho Jalkanen, CEO, Faron Outlook and Q&A session 3 27-FEB-2025 FINANCIAL STATEMENT RELEASE 2024
Slide 4: Financial Results 2024
Financial Results 2024 Yrjö Wichmann CFO, Faron 4 27-FEB-2025 FINANCIAL STATEMENT RELEASE 2024
Slide 5: Financial Results 2024 Overview
Financial Results 2024 Overview During 2024 • Cash balance of EUR 9.5 million at December 31, 2024 (2023: the cash position EUR 6.9 million). The company raised EUR 35.5 million was strengthened (gross) by combined transaction by a combined • Loss for the period of EUR –25.9 million for the year end
Slide 6: Subsequent/Post-period events
Financial Results 2024 Subsequent/Post-period events • In early February 2025, Faron conducted a private placement directed Financially to a limited number of institutional and other investors raising well EUR 12.0 million. The Placement was oversubscribed 1.8 times. • On February 27, 2025, the Comp
Slide 7: Faron's Transformative Year 2024
Faron’s Transformative Year 2024 Dr. Juho Jalkanen CEO, Faron 7 27-FEB-2025 FINANCIAL STATEMENT RELEASE 2024
Slide 8: Improved financial position
Improved financial position Faron’s financial position improved FEBRUARY 2024 MARCH & APRIL 2024 JUNE 2024 significantly during 2024 Faron announced Faron completed a Faron completed an an event of default bridge funding and oversubscriped due to reaching a cuts in head count transaction that raised
Slide 9: New leadership in 2024
New leadership in 2024 Progress under the new APRIL 2024 MAY 2024 AUGUST 2024 leadership Faron announced Faron announced Faron appointed team the change of Chair CEO and CFO Dr. Petri Bono as a new changes CMO and Yrjö Wichmann as a permanent CFO Tuomo Pätsi Dr. Juho Yrjö Wichmann Dr. Petri Board Ch
Slide 10: The new Scientific Advisory Board
The new Scientific Advisory Board announced in October 2024 International experts with Toni Choueiri, MD, FASCO Naval G. Daver, MD Professor Professor Harvard, USA MD Anderson, CCC depth and Tom Powles, MBBS, MRCP, MD Mika Kontro, MD, PhD expertise Professor Adjunct Professor Barts Cancer Center, Lo
Slide 11: Significant progress with bexmarilimab's clinical trials in 2024 (1/2)
Significant progress with Positive bexmarilimab’s clinical trials in 2024 (1/2) interaction with the FDA JANUARY 2024 MAY 2024 JULY 2024 AUGUST 2024 OCTOBER 2024 Faron’s lead asset Excellent Faron announced positive feedback from FDA granted Faron announced bexmarilimab clinical results the FDA rega
Slide 12: Significant progress with bexmarilimab's clinical trials in 2024 (2/2)
Significant progress with bexmarilimab’s clinical trials in 2024 (2/2) NOVEMBER 2024 DECEMBER 2024 DECEMBER 2024 The BEXMAB Faron filed a patent Faron presented BEXMAB phase II Faron received regulatory application around interim data at ASH annual meeting approval from results the use of soluble Cl
Slide 13: Strong start for 2025
Strong start for 2025 Faron is well- Continued JANUARY 2025 FEBRUARY 2025 FEBRUARY 2025 positioned strong to deliver on Faron announced Faron announced a Faron receives its core business momentum that final patient has been identified significantly oversubscribed positive EMA opinion on Orphan Drug
Slide 14: Outlook into 2025
Outlook into 2025 Phase 2 readouts, regulatory interactions, and business transactions April May/June End of Q2 End of Q3 Q4 2025 We are looking Top line Phase Detailed data FDA EOP2 Phase 2 Regulatory forward to 2 response presented at up- meeting and duration of feedback on keeping you up- rate an
Slide 15: Q&A
Q&A Dr. Juho Jalkanen Yrjö Wichmann CEO, Faron CFO, Faron 15 27-FEB-2025 FINANCIAL STATEMENT RELEASE 2024
Slide 16: Thank You
THANK YOU 16 27-FEB-2025 FINANCIAL STATEMENT RELEASE 2024